VHL Regional Portal
Information and Knowledge for Health
- português
- español
- english
- français
Advanced Search EVID@Easy
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
Avendaño-Solá, Cristina; Ramos-Martínez, Antonio; Muñez-Rubio, Elena; Ruiz-Antorán, Belen; Malo de Molina, Rosa; Torres, Ferran; Fernández-Cruz, Ana; Calderón-Parra, Jorge; Payares-Herrera, Concepcion; Díaz de Santiago, Alberto; Romera-Martínez, Irene; Pintos, Ilduara; Lora-Tamayo, Jaime; Mancheño-Losa, Mikel; Paciello, Maria L; Martínez-González, A L; Vidán-Estévez, Julia; Nuñez-Orantos, Maria J; Saez-Serrano, Maria Isabel; Porras-Leal, Maria L; Jarilla-Fernández, Maria C; Villares, Paula; de Oteyza, Jaime Pérez; Ramos-Garrido, Ascension; Blanco, Lydia; Madrigal-Sánchez, Maria E; Rubio-Batllés, Martin; Velasco-Iglesias, Ana; Paño-Pardo, José R; Moreno-Chulilla, J A; Muñiz-Díaz, Eduardo; Casas-Flecha, Inmaculada; Pérez-Olmeda, Mayte; García-Pérez, Javier; Alcamí, Jose; Bueno, Jose L; Duarte, Rafael F.
J Clin Invest ; 131(20)2021 10 15.
Article in English
| MEDLINE| ID: mdl-34473652
ABSTRACT
BACKGROUNDPassive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19. Evidence from controlled clinical trials is inconclusive.METHODSWe conducted a randomized, open-label, controlled clinical trial at 27 hospitals in Spain. Patients had to be admitted for COVID-19 pneumonia within 7 days from symptom onset and not on mechanical ventilation or high-flow oxygen devices. Patients were randomized 1:1 to treatment with CP in addition to standard of care (SOC) or to the control arm receiving only SOC. The primary endpoint was the proportion of patients in categories 5 (noninvasive ventilation or high-flow oxygen), 6 (invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), or 7 (death) at 14 days. Primary analysis was performed in the intention-to-treat population.RESULTSBetween April 4, 2020, and February 5, 2021, 350 patients were randomly assigned to either CP (n = 179) or SOC (n = 171). At 14 days, proportion of patients in categories 5, 6, or 7 was 11.7% in the CP group versus 16.4% in the control group (P = 0.205). The difference was greater at 28 days, with 8.4% of patients in categories 5-7 in the CP group versus 17.0% in the control group (P = 0.021). The difference in overall survival did not reach statistical significance (HR 0.46, 95% CI 0.19-1.14, log-rank P = 0.087).CONCLUSIONCP showed a significant benefit in preventing progression to noninvasive ventilation or high-flow oxygen, invasive mechanical ventilation or ECMO, or death at 28 days. The effect on the predefined primary endpoint at 14 days and the effect on overall survival were not statistically significant.TRIAL REGISTRATIONClinicaltrials.gov, NCT04345523.FUNDINGGovernment of Spain, Instituto de Salud Carlos III.
Subject(s)
COVID-19/therapy , SARS-CoV-2 , Aged , COVID-19/mortality , COVID-19/physiopathology , Combined Modality Therapy , Disease Progression , Female , Hospitalization , Humans , Immunization, Passive/adverse effects , Kaplan-Meier Estimate , Male , Middle Aged , Odds Ratio , Pandemics , Spain/epidemiology , Treatment Outcome , COVID-19 Serotherapy
2.
Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients.
Asherson, R A; Espinosa, G; Cervera, R; Gómez-Puerta, J A; Musuruana, J; Bucciarelli, S; Ramos-Casals, M; Martínez-González, A L; Ingelmo, M; Reverter, J C; Font, J; Triplett, D A.
Ann Rheum Dis ; 64(6): 943-6, 2005 Jun.
ABSTRACT
BACKGROUND: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterised by formation of microthrombi and fibrin deposition in the microvasculature. The catastrophic antiphospholipid syndrome (APS) is characterised by multiorgan thrombosis, mainly involving small vessels. A broad spectrum of disorders may develop DIC features; however, the catastrophic APS has not previously been recognised as a cause of DIC. OBJECTIVE: To analyse the clinical and laboratory characteristics of catastrophic APS patients with DIC features. METHODS: The web site based international registry of patients with catastrophic APS (CAPS registry) (http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM) was analysed and the cases with DIC features selected. RESULTS: In 173 patients with catastrophic APS, 23 (13%) were found with DIC features. The clinical and immunological characteristics were similar in catastrophic APS patients with and without DIC features; a significant difference was found only in the prevalence of thrombocytopenia (100% in patients with DIC features v 59% in those without DIC features). CONCLUSIONS: DIC features are not rare in catastrophic APS, supporting the need for systematic screening of antiphospholipid antibodies in all patients with DIC features without precipitating factors. The presence of DIC features in the context of an APS makes it imperative to rule out the catastrophic variant of this syndrome.
Subject(s)
Antiphospholipid Syndrome/diagnosis , Disseminated Intravascular Coagulation/diagnosis , Adolescent , Adult , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/therapy , Child , Diagnosis, Differential , Disseminated Intravascular Coagulation/blood , Disseminated Intravascular Coagulation/therapy , Female , Humans , Male , Middle Aged , Platelet Count , Registries , Treatment Outcome
Consulta Detalhada
(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))
Export
Export format:
Export:
This page Selected references (0) All references
RSS
View RSS Add RSS to My VHL
This page Selected references (0)
...
